Genmab DuoBody - Model PD-L1x4-1BB (GEN1046) - Proprietary Bispecific Antibody
DuoBody PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. DuoBody®-PD-L1x4-1BB is designed to elicit an anti-tumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation, using inert DuoBody IgG1 antibody format.
-
Most popular related searches
Clinical Trials
A Phase 1/2 clinical study of DuoBody®-PD-L1x4-1BB in solid tumors and a Phase 2 clinical study of DuoBody®-PD-L1x4-1BB as a single agent or in combination with another anti-cancer therapy in relapsed/refractory metastatic non-small cell lung cancer are ongoing.
Customer reviews
No reviews were found for Genmab DuoBody - Model PD-L1x4-1BB (GEN1046) - Proprietary Bispecific Antibody. Be the first to review!